Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 20, 2019 16:05 ET | Source: Emergent BioSolutions

Emergent BioSolutions Announces Granting of Marketing Authorization in Five EU Countries for Its Oral Typhoid Vaccine; Expands Availability Across Europe

GAITHERSBURG, Md., May 20, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has successfully obtained marketing authorization for its oral typhoid vaccine...
May 20, 2019 06:30 ET | Source: Emergent BioSolutions

Emergent BioSolutions to Participate in Series of Investor Conferences

GAITHERSBURG, Md., May 20, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that a member of the company’s senior management team will participate in the following...
May 15, 2019 16:05 ET | Source: Emergent BioSolutions

Emergent BioSolutions Prepares for Initial Shipments of AV7909 Anthrax Vaccine Candidate into the Strategic National Stockpile

GAITHERSBURG, Md., May 15, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that the Biomedical Advanced Research and Development Authority (BARDA) has informed the...
May 09, 2019 06:30 ET | Source: Emergent BioSolutions

Emergent BioSolutions to Hold Annual Meeting of Stockholders on Thursday, May 23, 2019 at 9:00 AM EDT; Webcast Will Be Available

GAITHERSBURG, Md., May 09, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) has announced that it will hold its Annual Meeting of Stockholders on Thursday, May 23, 2019 beginning at...
May 02, 2019 16:05 ET | Source: Emergent BioSolutions

Emergent BioSolutions Reports First Quarter 2019 Financial Results

Reaffirms full year 2019 financial forecast and operational goalsProvides Q2 2019 revenue forecast of $200M-$220M GAITHERSBURG, Md., May 02, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc....
April 18, 2019 07:22 ET | Source: Emergent BioSolutions

Emergent BioSolutions to Release First Quarter 2019 Financial Results and Conduct a Conference Call on May 2, 2019

GAITHERSBURG, Md., April 18, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Thursday, May 2, 2019 at 5:00 pm (Eastern Time) to discuss the financial...
April 16, 2019 06:30 ET | Source: Emergent BioSolutions

Emergent BioSolutions Announces Interim Results From Phase 2 Study Evaluating CHIKV-VLP, Chikungunya Virus Vaccine Candidate

GAITHERSBURG, Md., April 16, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced results from the interim analysis of its Phase 2 clinical study evaluating the safety and...
March 19, 2019 06:30 ET | Source: Emergent BioSolutions

Emergent BioSolutions Initiates Phase 3 Clinical Study to Evaluate AV7909 for Post-Exposure Prophylaxis of Anthrax

GAITHERSBURG, Md., March 19, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of a Phase 3 trial to evaluate the lot consistency, immunogenicity, and...
February 28, 2019 16:45 ET | Source: Emergent BioSolutions

Emergent BioSolutions Awarded U.S. Department of State Contract to Supply Medical Countermeasures For Chemical Warfare Agents

GAITHERSBURG, Md., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has signed an indefinite-delivery, indefinite-quantity (IDIQ) contract with the...
February 21, 2019 16:05 ET | Source: Emergent BioSolutions

Emergent BioSolutions Reports Fourth Quarter and Full Year 2018 Financial Results

GAITHERSBURG, Md., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) reported financial results for the quarter and year ended December 31, 2018. FINANCIAL HIGHLIGHTS (in...